<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Process" Owner="NLM">        <PMID Version="1">30107807</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1477-7819</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>16</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>14</Day>                    </PubDate>                </JournalIssue>                <Title>World journal of surgical oncology</Title>                <ISOAbbreviation>World J Surg Oncol</ISOAbbreviation>            </Journal>            <ArticleTitle>The mode of progressive disease affects the prognosis of patients with metastatic breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>169</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12957-018-1472-9</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">According to the Response Evaluation Criteria in Solid Tumors (RECIST), progressive disease (PD) is diagnosed under two conditions: an increase in size of pre-existing lesions (IS) and the appearance of new lesions (NL). We retrospectively investigated the difference in the prognosis between IS and NL.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients receiving drug therapies for metastatic breast cancer between 2004 and 2015 at our institution were reviewed. The survival time after NL and IS was compared and the frequency of NL with each drug calculated.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">For the 107 eligible patients, the survival time after NL at second-line chemotherapy was significantly worse than after IS (median survival time 4.3 months vs. 20.3 months, p = 0.0048). Maintenance therapy with bevacizumab or trastuzumab had a high frequency of NL (88.9%), and third-line eribulin had a low frequency of NL (16.7%). A multivariate analysis showed that NL at second-line chemotherapy was not an independent risk factor (hazard ratio 1.02, 95%; confidence interval 0.54-1.93, p = 0.95) for the total survival time.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with IS had a better survival after PD than those with NL. We may be able to avoid changing drug therapy for patients without NL and allow them to continue drug therapy for longer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mori</LastName>                    <ForeName>Ryutaro</ForeName>                    <Initials>R</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2651-4478</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan. moriry52@gmail.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Futamura</LastName>                    <ForeName>Manabu</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Morimitsu</LastName>                    <ForeName>Kasumi</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Asano</LastName>                    <ForeName>Yoshimi</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tokumaru</LastName>                    <ForeName>Yoshihisa</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kitazawa</LastName>                    <ForeName>Mai</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yoshida</LastName>                    <ForeName>Kazuhiro</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>14</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>World J Surg Oncol</MedlineTA>            <NlmUniqueID>101170544</NlmUniqueID>            <ISSNLinking>1477-7819</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2014 Jul;50(10):1847-53</RefSource>                <PMID Version="1">24726734</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2015 Dec 09;17(1):150</RefSource>                <PMID Version="1">27391598</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur Urol. 2013 Dec;64(6):994-1002</RefSource>                <PMID Version="1">23219086</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2011 Jun 1;29(16):2144-9</RefSource>                <PMID Version="1">21464403</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2009 Jan;45(2):228-47</RefSource>                <PMID Version="1">19097774</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2007 Sep 1;110(5):973-9</RefSource>                <PMID Version="1">17647245</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2010 Feb;119(3):621-31</RefSource>                <PMID Version="1">19915976</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1996 Aug;14(8):2197-205</RefSource>                <PMID Version="1">8708708</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2012 Apr;23(4):948-54</RefSource>                <PMID Version="1">21832285</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Drug therapy</Keyword>            <Keyword MajorTopicYN="N">Prognosis</Keyword>            <Keyword MajorTopicYN="N">Progressive disease</Keyword>            <Keyword MajorTopicYN="N">Secondary breast neoplasms</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>08</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30107807</ArticleId>            <ArticleId IdType="doi">10.1186/s12957-018-1472-9</ArticleId>            <ArticleId IdType="pii">10.1186/s12957-018-1472-9</ArticleId>            <ArticleId IdType="pmc">PMC6092765</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>